Niranjan B. Pandey

Niranjan B. Pandey

Auto-generated profile, based on publicly available information

Niranjan B. Pandey

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in OncoImmunology
Verified
Journal Article
Open access
AMAdam Mirando
Adam Mirando
APAkash Patil
Akash Patil
CRChristine I. Rafie
Christine I. Rafie
BCBrian J. Christmas
Brian J. Christmas
NPNiranjan B. Pandey
Niranjan B. Pandey
Aleksander PopelAleksander Popel
Aleksander Popel
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following a clinical trial that showed response rates in at least 43% of patients. While this approval marks a major advance in the treatment of TNBC it may be possible to improve the efficacy of ICI therapies through further modulation of the suppressive tumor immune microenvironment (TIME). Several factors may limit immune response in TNBC including aberrant growth factor signaling, such as VEGFR2 and cMet signaling, inefficient vascularization, poor delivery of drugs and immune cells, and the skewing of immune cell populations toward immunosuppressive phenotypes. Here we investigate the immune-modulating properties of AXT201, a novel 20 amino-acid integrin-binding peptide in two syngeneic mouse TNBC models: 4T1-BALB/c and NT4-FVB. AXT201 treatment improved survival in the NT4 model by 20% and inhibited the growth of 4T1 tumors by 47% over 22 days post-inoculation. Subsequent immunohistochemical analyses of 4T1 tumors also showed a 53% reduction in vascular density and a 184% increase in pericyte coverage following peptide treatment. Flow cytometry analyses demonstrated evidence of a more favorable anti-tumor immune microenvironment following treatment with AXT201, including significant decreases in the populations of T regulatory cells, monocytic myeloid-derived suppressor cells, and PD-L1 expressing cells and increased expression of T cell functional markers. Together, these findings demonstrate immune-activating properties of AXT201 that could be developed in combination with other immunomodulatory agents in the treatment of TNBC.

5 July 2026 in bioRxiv
Verified
Preprint
Open access
AMAdam Mirando
Adam Mirando
RSRaquel Lima e Silva
Raquel Lima e Silva
JSJIKUI SHEN
JIKUI SHEN
TRThomas J Robinson
Thomas J Robinson
JGJordan J Green
Jordan J Green
NPNiranjan B Pandey
Niranjan B Pandey
Retinal and choroidal vascular diseases are major causes of vision loss that require frequent intravitreal anti-VEGF therapy. Anti-angiogenic peptide AXT107 demonstrated efficacy in preclinical studies and was advanced to the clinical stage. To provide for sustained delivery of the peptide and avoid complications with intravitreal injection, we evaluated suprachoroidal delivery of AXT107 microparticles (MP-AXT107). The original, soluble AXT107 formulation was ineffective at inhibiting laser-induced choroidal neovascularization (CNV) in our rat model and was consequently reformulated as microparticles. MP-AXT107 demonstrated high peptide incorporation efficiency, reproducible morphology, and physical and chemical stability for at least 9 months under refrigerated storage. In the rat CNV model, suprachoroidal MP-AXT107 significantly reduced neovascular area by approximately 60% relative to vehicle controls. Safety and durability were evaluated in a 9-month GLP toxicology study in Gottingen minipigs following a single suprachoroidal injection of vehicle or MP-AXT107 (0.125-1.25 mg/eye). Transient increases in IOP and mild ocular inflammatory findings were observed immediately following administration but resolved rapidly without lasting effects. No treatment-related adverse ocular findings were observed during the remainder of the study, and the highest tested dose (1.25 mg/eye) was established as the no-observed-adverse-effect level. Bioanalysis at study completion demonstrated persistent AXT107 localization primarily within choroid/RPE and scleral tissues, with no signs of systemic exposure. Collectively, these findings demonstrate that suprachoroidal delivery of MP-AXT107 enables sustained anti-angiogenic activity with favorable ocular safety and prolonged tissue retention, supporting further clinical development as a durable therapy for retinal and choroidal vascular diseases.

22 August 2025 in bioRxiv
Verified
Preprint
Open access
NFNatsuki Furukawa
Natsuki Furukawa
ACAlex R. Chao
Alex R. Chao
WYWendy Yang
Wendy Yang
APAkash Patil
Akash Patil
ECEric Christenson
Eric Christenson
Aleksander PopelAleksander Popel
Aleksander Popel
Oncolytic peptides are amphipathic peptides that specifically induce cell death in cancer cells by rupturing the cell membrane. Despite their therapeutic potential, few have advanced to clinical trials, and none have been approved for cancer treatment, highlighting the need for more potent and safe candidates. Moreover, the structure-activity relationship (SAR) of oncolytic peptides remains poorly understood. To address these challenges, we designed a series of peptides based on the previously reported oncolytic peptide CKS1 and evaluated their activity to induce cancer cell death. By comparing the structures and the activities of these peptides, we discovered novel insights in the SAR of oncolytic peptides. Among the peptides, we identified NF27 as the most potent peptide. NF27 showed broad cytotoxicity across multiple cancer types but displayed minimal toxicity against healthy cells and low hemolysis. Cell death induced by NF27 was immunogenic and promoted infiltration of immune cells in murine tumors. In murine tumor models, NF27 effectively suppressed tumor growth and achieved complete eradication in some cases, with no observable side effects. These findings highlight NF27 as a promising lead peptide for the development of safe and effective oncolytic therapies. One Sentence Summary: We identified NF27, a novel oncolytic peptide that induces immunogenic cancer cell death and eradicates tumors with low toxicity via SAR study.

24 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NPNiranjan B. Pandey
Niranjan B. Pandey
AMAdam Mirando
Adam Mirando
TRThomas J. Robinson
Thomas J. Robinson
DADavid R. P. Almeida
David R. P. Almeida
SDSabin Dang
Sabin Dang
JGJordan J. Green
Jordan J. Green
Frequent injections remain a substantial burden in the treatment of neovascular age-related macular degeneration (nAMD). AXT107 (gersizangitide) is a long-acting, integrin-disrupting peptide designed for suprachoroidal administration. In the phase 1/2a, open-label DISCOVER trial, 15 participants with active nAMD received a single suprachoroidal injection of AXT107 microparticles at 0.125, 0.25, or 0.5 mg and were followed for 40 weeks. Safety and tolerability were the primary outcomes; visual acuity, retinal thickness, and time to protocol-specified rescue anti-vascular endothelial growth factor treatment were exploratory outcomes. No AXT107-related serious adverse events, clinically significant intraocular inflammation, or sustained intraocular pressure elevations were observed. Fourteen eyes met the protocol-specified baseline imaging criterion for efficacy analyses. Among these eyes, two treatment-experienced eyes completed 40 weeks without protocol-specified rescue, and a third first received protocol-specified rescue at week 36. Anatomical improvements were observed in at least one eye in each dose cohort, although responses varied. A single suprachoroidal injection of AXT107 was well tolerated in this small first-in-human study. The exploratory findings warrant evaluation in a controlled trial One Sentence Summary: Suprachoroidal AXT107 was well tolerated, with some eyes remaining free of protocol-specified rescue for up to 40 weeks.